ImageneBio, Inc.
IMA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMA
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates for immunology and inflammatory indications, with a lead program (img-007) in Phase 2 and a cash position of $94.7M as of June 30, 2026.
Key risk: Need for additional capital
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst for ImageneBio, Inc..
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates for immunology and inflammatory indications, with a lead program (img-007) in Phase 2 and a cash position of $94.7M as of June 30, 2026.
- ImageneBio is a clinical-stage biopharmaceutical company with no approved products or revenue from product sales [sec_mda · as of 2025-07-24].
- The company reported cash and equivalents of $94.7M as of June 30, 2026, with a net loss of $10.2M for the same period [sec].
- The lead product candidate, img-007, is in Phase 2 clinical development with a topline readout expected by December 31, 2026 [catalyst].
- ImageneBio has a limited operating history and expects to need substantial additional funding to support operations and development [sec_mda · as of 2025-07-24].
- The company's ability to generate revenue depends on the successful development and commercialization of one or more product candidates [sec_mda · as of 2025-03-06].
What works
- ImageneBio has a cash position of $94.7M as of June 30, 2026, which may provide a runway to fund operations for at least 12 months [sec].
- The company is advancing a Phase 2 clinical program (img-007) with a topline readout expected by year-end 2026, representing a potential near-term catalyst [catalyst].
- ImageneBio is targeting immunology and inflammatory indications, a large and active therapeutic area with multiple potential opportunities [sec_mda · as of 2025-07-24].
What to weigh
- ImageneBio has no approved products or revenue from product sales, and its ability to achieve profitability is uncertain [sec_mda · as of 2025-07-24].
- The company expects to need substantial additional funding to support operations and development, and may be unable to raise capital on favorable terms [sec_mda · as of 2025-07-24].
- Clinical development is subject to numerous risks, including successful enrollment, completion of trials, and obtaining regulatory approval [sec_mda · as of 2025-07-24].
- ImageneBio has a limited operating history as a public company, which adds uncertainty to its financial and operational outlook [sec_mda · as of 2025-03-06].
From the filings
Quoted directly from source documents.
ImageneBio is a clinical-stage biopharmaceutical company with no approved products.
“We are a clinical-stage biopharmaceuti”
SEC MD&A · March 10, 2025
The company expects to need substantial additional funding.
“we will need substantial additional funding to support our operations and pursue our strategy.”
SEC MD&A · July 24, 2025
Revenue generation depends on successful development and commercialization.
“our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more product candidates.”
SEC MD&A · March 6, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · img-007 — Phase 2 Readout: img-007 — Topline results from the Phase 2 trial of img-007 are expected, which will provide initial efficacy and safety data for the lead candidate.
Risks & what to watch (4)›
Key risks
- Need for additional capital — The company expects to need substantial additional funding to support operations and may be unable to raise it on favorable terms [sec_mda · as of 2025-07-24].
- Clinical development risks
- No approved products or revenue
- Limited operating history
What to watch
- Phase 2 topline data for img-007, expected by December 31, 2026 [catalyst].
- Cash runway and any future financing activities, as the company will need additional capital to fund operations [sec_mda · as of 2025-07-24].
- Progress in clinical trial enrollment and execution for img-007 [sec_mda · as of 2025-07-24].
- Any updates on regulatory interactions or partnerships that could impact development [sec_mda · as of 2025-07-24].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run ImageneBio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ImageneBio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
44.8 months
D/E 0.07
No tracked pipeline phase
1 candidate
1 upcoming, next in ~123d
4 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$18.8M
| Holder | Shares | Value |
|---|---|---|
| bvf inc/il | 1,110,002 | $5.6M |
| vanguard capital management llc | 650,310 | $3.3M |
| omega fund management, llc | 455,361 | $2.3M |
| orbimed advisors llc | 378,556 | $1.9M |
| rtw investments, lp | 334,445 | $1.7M |
| blackrock, inc. | 129,214 | $646K |
| citadel advisors llc | 124,345 | $622K |
| renaissance technologies llc | 81,696 | $408K |
| adage capital partners gp, l.l.c. | 66,666 | $333K |
| geode capital management, llc | 59,929 | $300K |
Showing top 10 of 35 institutional holders of ImageneBio, Inc.. Open the full 13F history after sign-in.
Governance
Frequently asked questions
What is the AI investment thesis for ImageneBio, Inc.?
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates for immunology and inflammatory indications, with a lead program (img-007) in Phase 2 and a cash position of $94.7M as of June 30, 2026.
What is ImageneBio, Inc.'s next catalyst?
ImageneBio, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: img-007" — expected December 31, 2026.
Who is the CEO of ImageneBio, Inc.?
Dr. Kristin Yarema Ph.D. is the chief executive officer of ImageneBio, Inc. (IMA).
Where is ImageneBio, Inc. headquartered?
ImageneBio, Inc. (IMA) is headquartered in San Diego, CA, United States.
What therapeutic areas does ImageneBio, Inc. focus on?
ImageneBio, Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.